SCHEMBL11973450

SCHEMBL11973450

COc1ccnc2c(NS(=O)(=O)c3ccccc3)cccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ SLC40A1 Q9NP59 18/20 1.00
▸ AGTR1 P30556 2/20 0.61
▸ MEN1 O00255 1/20 0.61
▸ KMT2A Q03164 1/20 0.61
▸ GLO1 Q04760 2/20 0.58
▸ G6PD P11413 1/20 0.58
▸ NFKBIA P25963 1/20 0.58
▸ METAP2 P50579 1/20 0.58
▸ METAP1 P53582 1/20 0.58
▸ PAX8 Q06710 1/20 0.58
▸ ATM Q13315 1/20 0.58
▸ TDP1 Q9NUW8 1/20 0.58
▸ CKS1B P61024 1/20 0.56
▸ SKP2 Q13309 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12475028 0.86 SLC40A1 (0.75) SLC40A1AGTR1MEN1KMT2AGLO1
SCHEMBL11972882 0.83 SLC40A1 (0.71) SLC40A1AGTR1MEN1KMT2ANFKBIA
SCHEMBL11973387 0.83 SLC40A1 (1.00) SLC40A1AGTR1MEN1KMT2AGLO1
SCHEMBL30925464 0.83 SLC40A1 (0.70) SLC40A1AGTR1MEN1KMT2AGLO1
SCHEMBL11973299 0.81 SLC40A1 (1.00) SLC40A1AGTR1GLO1G6PDNFKBIA
SCHEMBL27214176 0.81 SLC40A1 (0.67) SLC40A1AGTR1MEN1KMT2AGLO1
SCHEMBL11973700 0.80 SLC40A1 (0.80) SLC40A1AGTR1GLO1G6PDNFKBIA
SCHEMBL30925458 0.80 SLC40A1 (0.66) SLC40A1AGTR1MEN1KMT2AGLO1
SCHEMBL11973688 0.80 SLC40A1 (1.00) SLC40A1AGTR1MEN1KMT2AGLO1
SCHEMBL27947198 0.78 SLC40A1 (0.81) SLC40A1AGTR1GLO1G6PDNFKBIA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2675526-B1 NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS VIFOR (INTERNATIONAL) AG (CH) 2017-02-01 — — EP disclosed
US-9102688-B2 Sulfonaminoquinoline hepcidin antagonists VIFOR (INTERNATIONAL) AG (CH) 2015-08-11 — — US disclosed
US-9102688-B2 Sulfonaminoquinoline hepcidin antagonists VIFOR (INTERNATIONAL) AG (CH) 2015-08-11 — — US disclosed
US-9102688-B2 Sulfonaminoquinoline hepcidin antagonists VIFOR (INTERNATIONAL) AG (CH) 2015-08-11 — — US disclosed
US-20140364424-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists VIFOR (INTERNATIONAL) AG (CH) 2014-12-11 — — US disclosed
US-20140364424-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists VIFOR (INTERNATIONAL) AG (CH) 2014-12-11 — — US disclosed
US-20140364424-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists VIFOR (INTERNATIONAL) AG (CH) 2014-12-11 — — US disclosed
US-20120214803-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists VIFOR (INTERNATIONAL) AG (CH) 2012-08-23 — — US disclosed
US-20120214803-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists VIFOR (INTERNATIONAL) AG (CH) 2012-08-23 — — US disclosed
US-20120214803-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists VIFOR (INTERNATIONAL) AG (CH) 2012-08-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214803-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists HAMP, SLC40A1, FTH1 SLC40A1 2/4885AGTR1 2153/4885MEN1 2680/4885
US-20140364424-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists HAMP, SLC40A1, FTH1 SLC40A1 2/4885AGTR1 2153/4885MEN1 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback